Evidence map›Paper›PMID 41137901›Full record

ArticleAnnals of hematology2025

BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy.

Paride Bartolucci, Federica Gigli, Valentina Tabanelli, Arianna Valeriano, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, Enrico Derenzini

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paride BartolucciDivision of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. paride.bartolucci@ieo.it.
Federica GigliDivision of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Valentina TabanelliDivision of Haematopathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Arianna ValerianoLaboratory of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Giuliana GregatoLaboratory of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Claudia PolettiLaboratory of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Francesco BertoliniLaboratory of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Enrico DerenziniDivision of Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 51-year-old male patient initially diagnosed with JAK2-V617F-mutated polycythemia vera (PV), who developed chronic phase BCR::ABL1-positive chronic myeloid leukemia (CML) 11 years later. The patient was treated with hydroxyurea and later with ruxolitinib (RUX) for PV. Following CML diagnosis, treatment with imatinib combined with RUX was initiated. Imatinib and RUX combination therapy proved to be safe and well-tolerated without major adverse events. After over one year of treatment, the patient maintained a complete cytogenetic response and a MR

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFusion Proteins, bcr-ablJanus Kinase 2Leukemia, Myelogenous, Chronic, BCR-ABL PositivePolycythemia VeraPyrazolesHumansImatinib MesylateMaleMiddle AgedMutationNitrilesPyrimidinesBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImatinib MesylateJAK2 protein, humanJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinibBCR-ABL mutationsBCR-ABL positiveCase reportsChronicCoexistence of JAK2CombinationDrug therapyImatinib mesylateJAK2V617 mutationLeukemiaMyelogenousMyeloproliferative disordersPolycythemia veraRuxolitinib

Identifiers

PMID41137901
PMCPMC12672772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.